Tarek Hassanein, MD
Hepatology · Coronado, CANPI 1801854450
Payments from drug & device makers
Across 2,011 payments — averaging $2792.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.2M
- Grifols Therapeutics LLC$617K
- Gilead$491K
- Boehringer Ingelheim$450K
- Bausch Health US, LLC$440K
- Novartis$308K
- plus $2.2M from 51 others
Across 31 payments — averaging $1968.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$42K
- Eli Lilly$19K
- Provepharm Inc.$70
What the payments were for
- Consulting fees$43,84816%
- Speaking & faculty fees$192,91869%
- Travel & lodging$25,6269%
- Food & beverage$12,0164%
- Education$3180%
- Other$3,3801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,615,905 in reported general payments places this provider in the 95th percentile of 36 hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpdivoNivolumab | 39 | $589,097 |
| ImjudoTremelimumab-Actl | 13 | $516,885 |
| XifaxanRifaximin | 126 | $438,024 |
| ImfinziDurvalumab | 26 | $326,473 |
| EpclusaSofosbuvir/Velpatasvir | 11 | $258,863 |
| VemlidyTenofovir Alafenamide | 95 | $151,034 |
| RezdiffraResmetirom | 15 | $60,144 |
| OzempicSemaglutide | 39 | $43,802 |
| Ursodiol | 240 | $28,745 |
| LinzessLinaclotide | 39 | $23,178 |
| Entecavir | 62 | $10,139 |
| Albuked-25Albumin Human | 21 | $4,028 |
| Lansoprazole | 116 | $3,676 |
| Tacrolimus | 86 | $3,292 |
| Lactulose | 84 | $3,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaImjudo, Imfinzi | $7,932 | $843,35839 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo | $279,988 | $589,09739 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $438,024126 claims |
| GileadEpclusa, Vemlidy | $491,030 | $409,897106 claims |
| Madrigal PharmaceuticalsRezdiffra | $80,810 | $60,14415 claims |
| Novo NordiskOzempic | $24 | $43,80239 claims |
| AbbVieLinzess | $1,154,922 | $23,17839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 hepatology providers in California.
Other hepatology in Coronado
- Edward MenaPasadena$4.9M
- Robert GishFolsom$1.9M
- Maurizio BonaciniSan Francisco$1.2M
- Walid AyoubWest Hollywood$1.1M
- Lisa NybergSan Diego$903K
- Vinay SundaramLos Angeles$725K
- Marina RoytmanFresno$685K
- Amandeep SahotaLos Angeles$663K
- Sergio RojterLos Angeles$358K
- Alexander KuoWest Hollywood$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.